PLEASANTON, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Thoratec Corporation , a world leader in products to treat cardiovascular disease, today announced that it will report its operating results for the 2007 fiscal year on Tuesday, February 5.
The company will hold a conference call to discuss its financial results and operating activities to all interested parties at 8:00 a.m., Pacific Standard Time, (11:00 a.m., Eastern Standard Time), Tuesday, February 5, hosted by Gary F. Burbach, president and chief executive officer, and David Smith, executive vice president and chief financial officer.
The teleconference call can be accessed by calling (913) 312-6698, passcode 4229045. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will also be available on the Internet at phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=95989&eventID=1751127 or at http://www.thoratec.com.
A replay of the conference call will be available through Tuesday, February 12, via http://www.thoratec.com or by telephone at (719) 457-0820, passcode 4229045.
Thoratec Corporation is a world leader in therapies to address advanced stage heart failure. The company’s product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 11,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web sites at http://www.thoratec.com or http://www.itcmed.com
CONTACT: David Smith, Executive Vice President, Chief Financial Officer of
Thoratec Corporation, +1-925-847-8600; or Neal B. Rosen of Ruder-Finn West,
+1-415-692-3058, for Thoratec Corporation
Web site: http://www.thoratec.com/
http://www.itcmed.com/
